Publications by authors named "Huiyan Luo"

Background: Head and neck squamous cell carcinoma(HNSCC) is the sixth most common malignancy worldwide, with more than 890,000 new cases and 450,000 deaths annually. Its major risk factors include smoking, alcohol abuse, aging, and poor oral hygiene. Due to the lack of early and effective detection and screening methods, many patients are diagnosed at advanced stages with a five-year survival rate of less than 50%.

View Article and Find Full Text PDF

This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxaliplatin) as a first-line treatment for unresectable metastatic colorectal cancer (mCRC). In this phase 2 study, a total of 62 patients with untreated, histologically confirmed colorectal adenocarcinoma and no prior systemic therapy for metastatic disease were enrolled. Patients received SHR-1701 (30 mg/kg), bevacizumab (7.

View Article and Find Full Text PDF

In many clinical and research settings, the scarcity of high-quality medical imaging datasets has hampered the potential of artificial intelligence (AI) clinical applications. This issue is particularly pronounced in less common conditions, underrepresented populations and emerging imaging modalities, where the availability of diverse and comprehensive datasets is often inadequate. To address this challenge, we introduce a unified medical image-text generative model called MINIM that is capable of synthesizing medical images of various organs across various imaging modalities based on textual instructions.

View Article and Find Full Text PDF

Colorectal adenomas (CRAs) represent precancerous lesions that precede the development of colorectal cancer (CRC). Regular monitoring of CRAs can hinder the progression into carcinoma. To explore the utility of tissue DNA and circulating cell-free DNA (cfDNA) in early diagnosis of CRC, we retrospectively sequenced paired tissue and plasma samples from 85 patients with conventional CRAs.

View Article and Find Full Text PDF

Purpose: Neoadjuvant immunochemotherapy (NAIC) markedly induces pathologic regression in locally advanced gastric adenocarcinoma (GAC). However, specific biomarkers are still lacking to effectively identify the beneficiary patients for NAIC.

Patients And Methods: A prospective, single-arm, phase II study was conducted to treat locally advanced GAC with NAIC (NCT05515796).

View Article and Find Full Text PDF

Gastric cancer is a malignant tumor that ranks third in cancer-related deaths worldwide. Early-stage gastric cancer can often be effectively managed through surgical resection. However, the majority of cases are diagnosed in advanced stages, where outcomes with conventional radiotherapy and chemotherapy remain unsatisfactory.

View Article and Find Full Text PDF

Lung cancer is one of the most common malignant tumours worldwide and its high mortality rate makes it a leading cause of cancer-related deaths. To address this daunting challenge, we need a comprehensive understanding of the pathogenesis and progression of lung cancer in order to adopt more effective therapeutic strategies. In this regard, integrating multi-omics data of the lung provides a highly promising avenue.

View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer (CRC) is a significant global health issue, and this study investigates how the oral microbiome may play a role in its development using Mendelian Randomization (MR) with extensive gene and microbiome data from China and Japan.
  • The research analyzed microbiome samples and genetic data to identify 19 bacterial taxa associated with CRC, some providing protective effects while others increased risk, along with pathways impacted by these microbes.
  • The findings emphasize the oral microbiome's involvement in CRC risk, revealing potential therapeutic options like Menadione Sodium Bisulfite and Raloxifene, paving the way for more personalized treatment approaches for colorectal cancer.
View Article and Find Full Text PDF

Background: The anti-PD-L1 antibody durvalumab has been approved for use in first-line advanced biliary duct cancer (ABC). So far, predictive biomarkers of efficacy are lacking.

Methods: ABC patients who underwent gemcitabine-based chemotherapy with or without durvalumab were retrospectively enrolled, and their baseline clinical pathological indices were retrieved from medical records.

View Article and Find Full Text PDF

Breast cancer (BC) is one of the most common and fatal malignancies among women worldwide. Circadian rhythms have emerged in recent studies as being involved in the pathogenesis of breast cancer. In this paper, we reviewed the molecular mechanisms by which the dysregulation of the circadian genes impacts the development of BC, focusing on the critical clock genes, brain and muscle ARNT-like protein 1 (BMAL1) and circadian locomotor output cycles kaput (CLOCK).

View Article and Find Full Text PDF

Epithelial ovarian cancer (EOC) is the deadliest women's cancer and has a poor prognosis. Early detection is the key for improving survival (a 5-year survival rate in stage I/II is over 70% compared to that of 25% in stage III/IV) and can be achieved through methylation markers from circulating cell-free DNA (cfDNA) using a liquid biopsy. In this study, we first identify top 500 EOC markers differentiating EOC from healthy female controls from 3.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the effectiveness of immune checkpoint blockades combined with chemotherapy in metastatic gastric cancer (mGC) and introduces a TMEscore model to evaluate the tumor microenvironment (TME) as a potential biomarker for treatment response.* -
  • A total of 86 tumor samples were analyzed from patients in a multi-center trial, showing that a higher TMEscore correlated with better treatment responses (31.4% overall response rate), with TMEscore-high patients achieving a 59% response rate and improved survival outcomes.* -
  • The TMEscore outperformed other biomarkers like MSI and CPS for predicting patient responses, indicating its potential as a reliable tool for identifying mGC patients who could benefit from ICB and
View Article and Find Full Text PDF

Melanoma, a malignant skin cancer arising from melanocytes, exhibits rapid metastasis and a high mortality rate, especially in advanced stages. Current treatment modalities, including surgery, radiation, and immunotherapy, offer limited success, with immunotherapy using immune checkpoint inhibitors (ICIs) being the most promising. However, the high mortality rate underscores the urgent need for robust, non-invasive biomarkers to predict patient response to adjuvant therapies.

View Article and Find Full Text PDF

Background: The interim analysis of the randomized phase 3 ESCORT-1st study demonstrated significantly longer overall survival (OS) and progression-free survival (PFS) for camrelizumab-chemotherapy than placebo-chemotherapy in untreated advanced/metastatic esophageal squamous cell carcinoma (ESCC). Here, we present the final analysis of this study and investigate potential indicators associated with OS.

Methods: Patients were randomized 1:1 to receive camrelizumab (200 mg) or placebo, both in combination with up to six cycles of paclitaxel (175 mg/m) and cisplatin (75 mg/m).

View Article and Find Full Text PDF

Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined. Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment.

View Article and Find Full Text PDF
Article Synopsis
  • A clinical trial was conducted to compare the effectiveness and safety of two treatments—cetuximab plus FOLFOXIRI (triplet therapy) and cetuximab plus FOLFOX (doublet therapy)—in RAS/BRAF wild-type colorectal cancer patients who had unresectable liver metastases.
  • The study enrolled 146 patients across seven medical centers in China between April 2018 and December 2022, assessing their objective response rate and other outcomes such as tumor response and survival.
  • Results showed that the response rates were similar between the two treatment groups (84.7% for triplet vs. 79.7% for doublet), indicating no significant difference in efficacy, and the trial also monitored
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on neoadjuvant and adjuvant immunotherapies for cancer, analyzing their similarities and differences using informatics and extensive literature reviews from 2014 to 2023.
  • It involved a detailed retrospective analysis of 1373 studies, assessing variables like publication volume, citation volume, and connection strength to detect trends and research clusters.
  • Results showed significant growth in neoadjuvant therapies (25.18% annually) compared to adjuvant therapies (6.52%), with emerging research areas identified, particularly around efficacy, safety, and key biomarkers impacting these therapy strategies.
View Article and Find Full Text PDF
Article Synopsis
  • - The CAPability-01 trial studied the effectiveness of combining the PD-1 antibody sintilimab with the HDAC inhibitor chidamide, with or without the VEGF antibody bevacizumab, in patients who have advanced colorectal cancer resistant to chemotherapy.
  • - Results showed that the combination therapy (triplet arm) significantly improved progression-free survival and overall response rates compared to the dual therapy (doublet arm), indicating increased treatment efficacy.
  • - Patients experienced various adverse side effects, with two treatment-related deaths reported; however, the analysis suggested the triplet therapy led to enhanced immune activity in the tumor environment.
View Article and Find Full Text PDF

Background: To provide data on the safety and efficacy of a combination chemotherapy regimen consisting of S-1, oxaliplatin, and irinotecan (SOXIRI) as a first-line therapy in unresectable pancreatic ductal adenocarcinoma (UPDA) patients.

Methods: Patients with UPDA and no prior treatment chemotherapy in the UPDA setting were enrolled. The primary endpoint was the objective response rate (ORR).

View Article and Find Full Text PDF

Background: In the past, many meta-analyses (MAs) suggested that elemene injection (EI) played a complementary and alternative role in cancer treatment. However, some results were contradictory and a lot of evidences weren't classified. Thus, their clinical guidance effect was very limited.

View Article and Find Full Text PDF

Background: Conflicting results about the effect of concomitant medications on immunotherapy in non-small cell lung cancer (NSCLC) were reported by many meta-analyses (MAs), and the certainty of evidence linking concomitant medications with immunotherapy efficacy has not been quantified, which may cause some evidence to be misinterpreted.

Methods: Four databases including Embase, Cochrane Library, PubMed, and Web of Science were searched from inception to January 2023 in English. Based on prospective or retrospective clinical controlled trials including immunotherapy with concomitant medications or not in NSCLC, quantitative MAs reporting the efficacy of immunotherapy with binary direct comparison and enough extractable data were collected.

View Article and Find Full Text PDF